Real-world (RW) use patterns, effectiveness, and tolerability of sacituzumab govitecan (SG) for second-line (2L) and later treatment of metastatic triple-negative breast cancer (mTNBC)

被引：0
|
作者：
Kalinsky, K. [1 ]
Spring, L. [2 ,3 ]
Yam, C. [4 ]
Ntalla, I. [5 ]
Stwalley, B. [6 ]
Sjekloca, N. [7 ]
Lai, C. [8 ]
Kaushiva, A. [9 ]
Taylor, A. J. [10 ]
Nanda, R. [11 ]
机构：
[1] Emory Univ, Winship Canc Inst, Hematol & Med Oncol, Atlanta, GA USA
[2] Massachusetts Gen Hosp Canc Ctr, Hematol Oncol, Boston, MA USA
[3] Harvard Med Sch, Boston, MA USA
[4] Univ Texas MD Anderson Canc Ctr Houston, Dept Breast Med Oncol, Houston, TX USA
[5] Gilead Sci Europe Ltd, Real World Evidence, Stockley Pk, Uxbridge, England
[6] Gilead Sci Inc, US Med Affairs, Foster City, CA USA
[7] Gilead Sci Europe Ltd, Global Med Affairs, Oncol, Stockley Pk, Uxbridge, England
[8] Gilead Sci Inc, Clin Dev, Foster City, CA USA
[9] Concert AI, Real World Data & Evidence, Cambridge, MA USA
[10] Gilead Sci Europe Ltd, Real World Evidence, Stockley Pk, Uxbridge, England
[11] Univ Chicago Med, Dept Med Sect Hematol Oncol, Chicago, IL USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.570
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
393P
引用
收藏
页码：S345 / S346
页数：2
相关论文
共 50 条
  • [1] Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States
    Kalinsky, Kevin
    Spring, Laura
    Yam, Clinton
    Bhave, Manali Ajay
    Ntalla, Ioanna
    Lai, Catherine
    Sjekloca, Nikoleta
    Stwalley, Brian
    Stokes, Michael
    Taylor, Aliki
    Nanda, Rita
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 208 (01) : 203 - 214
  • [2] Metastatic triple-negative Breast Cancer (mTNBC) - Second-line Therapy mTNBC: Sacituzumab Govitecan with high Effectiveness even in HER2-low
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (7-8) : 343 - 343
  • [3] SARELIFE: An Italian, multicentric real-world study of sacituzumab govitecan (SG) in pretreated metastatic triple-negative breast cancer (mTNBC)
    Cona, M. S.
    Ruggieri, L.
    Artale, S. A. A.
    Catania, G.
    D'Auria, G.
    Gallerani, E.
    Villa, F.
    Gambaro, A.
    Chirco, A.
    Giordano, M.
    Pistelli, M.
    Verderame, F.
    Bramati, A.
    Stani, S. C.
    Vici, P.
    Meattini, I.
    Tagliaferri, B.
    Tedesco, B.
    Amato, O.
    La Verde, N. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S381 - S382
  • [4] COST-EFFECTIVENESS ANALYSIS OF SACITUZUMAB GOVITECAN AS SECOND-LINE TREATMENT FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN JAPAN
    Yamaguchi, M.
    Maeda, T.
    Morimoto, K.
    Chen, W.
    Moriwaki, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2023, 26 (06) : S106 - S106
  • [5] Real-world outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) in 2L+in the United States (US)
    Kalinsky, Kevin
    Spring, Laura
    Yam, Clinton
    Taylor, Aliki
    Sjekloca, Nikoleta
    Kaushiva, Alpana
    Lai, Catherine
    Ntalla, Ioanna
    Nanda, Rita
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated in second line (2L) in the US real-world setting
    Luhn, P.
    O'Hear, C.
    Ton, T. G.
    Hsieh, A.
    Yi, J.
    Chang, C-W
    Funke, R.
    Kurian, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [7] Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
    Lisa A. Carey
    Delphine Loirat
    Kevin Punie
    Aditya Bardia
    Véronique Diéras
    Florence Dalenc
    Jennifer R. Diamond
    Christel Fontaine
    Grace Wang
    Hope S. Rugo
    Sara A. Hurvitz
    Kevin Kalinsky
    Joyce O’Shaughnessy
    Sibylle Loibl
    Luca Gianni
    Martine Piccart
    Yanni Zhu
    Rosemary Delaney
    See Phan
    Javier Cortés
    npj Breast Cancer, 8
  • [8] Real-world treatment patterns and outcomes among patients (pts) with second-line (2L) and third-line (3L) metastatic triple-negative breast cancer (mTNBC) in England using the Cancer Analysis System (CAS).
    Chang, Lawrence
    Hall, Peter S.
    Preger, Luciana
    Sjekloca, Nikoleta
    Bergamaco, Estevan
    Broe, Anne
    Petrova, Plamena
    Berg, Paul
    Reich, Adam
    Pawar, Neha
    Gharaibeh, Mahdi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results
    Seneviratne, Lasika C.
    Harnden, Kathleen Kiernan
    Blau, Sibel
    Danso, Michael A.
    Berz, David
    Guaqueta, Delia Constanza
    Schwerkoske, John F.
    O'Shaughnessy, Joyce
    Patt, Debra A.
    Bardia, Aditya
    McCann, Kelly Elizabeth
    Beelen, Andrew Paul
    Zhang, Jingshan
    Yi, John S.
    Hurvitz, Sara A.
    Mardones, Mabel Alejandra
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Pharmacokinetics (PK) of sacituzumab govitecan (SG) in patients (Pts) with metastatic triple-negative breast cancer (mTNBC) and other solid tumors
    Sathe, A. G.
    Singh, I.
    Singh, P.
    Diderichsen, P.
    Wang, X.
    Chang, P.
    Phan, S-C.
    Girish, S.
    Othman, A. A.
    ANNALS OF ONCOLOGY, 2022, 33 : S214 - S214
12345